Opinion|Videos|July 10, 2024
Primary Differences in the Toxicity Profiles of Abemaciclib and Ribociclib
A panel of experts compare the toxicity profiles of abemaciclib and ribociclib.
Advertisement
Video content above is prompted by the following questions:
- What are the primary differences in the toxicity profiles of abemaciclib and ribociclib when used in the adjuvant setting, and how are these prioritized when selecting a CDK4/6 inhibitor?
- Discuss the recent publication of long-term patient-reported outcomes with adjuvant abemaciclib.
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
FDA OKs Zidesamtinib as New Option for Resistant ROS1+ NSCLC
2
Cognitive Rehabilitation Improves Functional Outcomes in Long COVID Brain Fog
3
PMOS Linked to 4-Fold Atherosclerotic Heart Disease Risk in 2.5 Million US Women
4
CAR T-Cell Therapy Shows Promise in Refractory Myasthenia Gravis, Evidence Still Limited
5